Boston, MA, May 03, 2015 –(PR.com)– Curemeta LLC, a Boston-based biotech focused on developing antibody drug conjugate therapies for metastatic cancers, announced that they will be presenting their data on novel ADC therapies at the essential Protein Engineering Summit (PEGS) taking place at the Seaport World Trade Center in Boston on May 4-8, 2015. CEO Mike Schopperle will be speaking on Tuesday May 5 at 9AM on this topic. Scientist Yawen Ju has been selected for an oral presentation on Thursday May 7.
The following posters will be presented in sessions on Monday May 4, 2015 between 9AM and 3:30PM. The last one will be on Thursday May 7:
“Immunohistochemical Analysis with Pluripotent Stem Cell Specific Antibodies is Predictive of Survival in Colonic Carcinoma”
Immunohistochemistry done by us and analyzed by our expert pathologist indicate a strong correlation between our target and aggressive cancers
“Development of Pluripotent Specific Antibodies for Novel Cancer Therapeutics”
A snapshot of how our antibodies were developed as seen through our multiple assays
“Evaluation of high-affinity antibodies specific to pluripotent stem cells for the diagnosis of aggressive and metastatic cancers”
A preclinical study on capturing circulating pluripotent cancer stem cells in metastatic cancer patients.
“ADCs Targeting Pluripotent Stem Cells”
A definitive look at the idea behind how these ADCs work and why they work
CureMeta is a Boston-based biotech bringing a unique approach to oncology research by developing new and powerful drugs to target metastatic cancers. Based on ideas and concepts linking cell pluripotency with metastatic and aggressive cancers, CureMeta is building a platform of potential cancer drug therapies through targeted antibody drug conjugates.
For more information, please contact An Holmqvist by email at email@example.com or visit www.curemeta.com